JP2015509110A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509110A5
JP2015509110A5 JP2014555351A JP2014555351A JP2015509110A5 JP 2015509110 A5 JP2015509110 A5 JP 2015509110A5 JP 2014555351 A JP2014555351 A JP 2014555351A JP 2014555351 A JP2014555351 A JP 2014555351A JP 2015509110 A5 JP2015509110 A5 JP 2015509110A5
Authority
JP
Japan
Prior art keywords
tautomer
compound
pharmaceutically acceptable
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014555351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509110A (ja
JP6002785B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/050555 external-priority patent/WO2013114250A1/en
Publication of JP2015509110A publication Critical patent/JP2015509110A/ja
Publication of JP2015509110A5 publication Critical patent/JP2015509110A5/ja
Application granted granted Critical
Publication of JP6002785B2 publication Critical patent/JP6002785B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014555351A 2012-02-03 2013-01-22 ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体 Expired - Fee Related JP6002785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594460P 2012-02-03 2012-02-03
US61/594,460 2012-02-03
PCT/IB2013/050555 WO2013114250A1 (en) 2012-02-03 2013-01-22 Benziimidazole and imidazopyridine derivatives as sodium channel modulators

Publications (3)

Publication Number Publication Date
JP2015509110A JP2015509110A (ja) 2015-03-26
JP2015509110A5 true JP2015509110A5 (cg-RX-API-DMAC7.html) 2016-02-12
JP6002785B2 JP6002785B2 (ja) 2016-10-05

Family

ID=47846092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555351A Expired - Fee Related JP6002785B2 (ja) 2012-02-03 2013-01-22 ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体

Country Status (9)

Country Link
US (1) US8927587B2 (cg-RX-API-DMAC7.html)
EP (1) EP2809655B1 (cg-RX-API-DMAC7.html)
JP (1) JP6002785B2 (cg-RX-API-DMAC7.html)
AR (1) AR089865A1 (cg-RX-API-DMAC7.html)
CA (1) CA2861439C (cg-RX-API-DMAC7.html)
ES (1) ES2548228T3 (cg-RX-API-DMAC7.html)
TW (1) TW201341370A (cg-RX-API-DMAC7.html)
UY (1) UY34602A (cg-RX-API-DMAC7.html)
WO (1) WO2013114250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134306A1 (en) 2013-03-01 2014-09-04 Zalicus Pharmaceuticals, Ltd. Heterocyclic inhibitors of the sodium channel
ES2986650T3 (es) 2013-12-13 2024-11-12 Vertex Pharma Proceso y productos intermedios para preparar profármacos de amidas de piridona útiles como moduladores de los canales de sodio
WO2015127549A1 (en) * 2014-02-27 2015-09-03 Hassan Pajouhesh Heterocyclic inhibitors of the sodium channel
JP2017516803A (ja) 2014-05-30 2017-06-22 ファイザー・インク ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
PT3348547T (pt) * 2015-09-11 2020-10-12 Sumitomo Dainippon Pharma Co Ltd Derivados de benzimidazole como inibidores de nav 1.7 (canal de sódio, controlado por tensão, tipo ix, subunidade alfa (scn9a)) para o tratamento de dor, disúria e esclerose múltipla
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
ES2927712T3 (es) 2017-05-16 2022-11-10 Vertex Pharma Amidas deuteradas de piridona y profármacos de las mismas como moduladores de canales de sodio
JPWO2018212162A1 (ja) * 2017-05-17 2020-03-19 株式会社トクヤマ ジアミノベンゼン化合物の製造方法
ES3008911T3 (en) 2017-07-11 2025-03-25 Vertex Pharma Carboxamides as modulators of sodium channels
ES2963417T3 (es) * 2018-01-15 2024-03-27 UCB Biopharma SRL Derivados de imidazol condensados como moduladores de IL-17
TW202002971A (zh) 2018-02-12 2020-01-16 美商維泰克斯製藥公司 治療疼痛的方法
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
PT4069691T (pt) 2019-12-06 2024-12-18 Vertex Pharma Tetrahidrofuranos substituídos como moduladores dos canais de sódio
US20230167121A1 (en) * 2020-04-14 2023-06-01 The Trustees Of The University Of Pennsylvania Substituted {1,2,4,} triazolo{1,5-a} pyrimidine compounds and use in stabilizing microtubules
WO2022108849A1 (en) * 2020-11-17 2022-05-27 Arisan Therapeutics Inc. Heterocyclic compounds as therapeutic agents
AU2022286438A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
WO2022256702A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
EP4346818B1 (en) 2021-06-04 2025-12-03 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
CN117858875A (zh) 2021-06-04 2024-04-09 沃泰克斯药物股份有限公司 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
GEAP202416430A (en) 2021-06-04 2024-03-25 Vertex Pharma N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
CN114249654B (zh) * 2021-12-30 2023-11-14 江苏广域化学有限公司 烷基苯胺类化合物的制备方法
KR20240134944A (ko) 2022-01-18 2024-09-10 쳉두 캉홍 파마슈티칼 코., 엘티디. 방향족 융합 고리 nav1.8 억제제 및 이의 용도
CN114288289A (zh) * 2022-02-17 2022-04-08 昆山彭济凯丰生物科技有限公司 具有镇痛和/或止痒功能的药物组合物及其应用
WO2023205778A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CA3257285A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
JP2025513454A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN119677737A (zh) 2022-04-22 2025-03-21 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
JP2025516005A (ja) 2022-04-25 2025-05-23 サイトワン セラピューティクス インコーポレイテッド 疼痛の処置のためのnav1.8の二環式複素環アミド阻害剤
IL321269A (en) 2022-12-06 2025-08-01 Vertex Pharma Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
CN116621789A (zh) * 2023-05-31 2023-08-22 上海吉奉生物科技有限公司 一种(4s)-3-[2-[[芴甲氧羰基]氨基]乙酰基]-2,2-二甲基-4-恶唑烷羧酸的合成方法
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202523313A (zh) 2023-10-23 2025-06-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8604566D0 (sv) * 1986-10-27 1986-10-27 Haessle Ab Novel compunds
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2425185A1 (en) * 2000-10-06 2002-04-11 Stephane De Lombaert Benzimidazole and indole derivatives as crf receptor modulators
US7022714B2 (en) * 2002-07-31 2006-04-04 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
JP4800216B2 (ja) * 2003-10-24 2011-10-26 エグゼリクシス, インコーポレイテッド p70S6キナーゼモジュレーターおよび使用方法
WO2005113580A1 (en) 2004-05-21 2005-12-01 Pfizer Inc. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
AU2007233179A1 (en) * 2006-03-31 2007-10-11 Astrazeneca Ab Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators
BRPI0717596B8 (pt) 2006-10-18 2021-05-25 Pfizer Prod Inc compostos de éter biarílico uréia, seu uso e composição farmacêutica que os compreende
US20080207683A1 (en) * 2007-02-15 2008-08-28 Darin Allen Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
ATE461177T1 (de) 2007-03-23 2010-04-15 Icagen Inc Ionenkanal-hemmer
MX2009011816A (es) 2007-05-03 2009-11-19 Pfizer Ltd Derivados de piridina.
CA2685952C (en) 2007-05-03 2012-03-13 Pfizer Limited N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
EP2234486A4 (en) * 2007-12-19 2011-09-14 Scripps Research Inst BENZIMIDAZOLES AND ANALOGS AS INHIBITORS OF RHO-KINASE
EP2072516A1 (en) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists
US8628695B2 (en) 2008-04-18 2014-01-14 E I Du Pont De Nemours And Company Surface-modified ruthenium oxide conductive material, lead-free glass(es), thick film resistor paste(s), and devices made therefrom
TW201028142A (en) * 2008-10-30 2010-08-01 Biogen Idec Inc Heterobicyclic sphingosine 1-phosphate analogs
JP5667934B2 (ja) * 2010-06-28 2015-02-12 大日本住友製薬株式会社 新規2環性複素環化合物からなる医薬
EP2681200A4 (en) * 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL

Similar Documents

Publication Publication Date Title
JP2015509110A5 (cg-RX-API-DMAC7.html)
JP2018537413A5 (ja) 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
JP2014506907A5 (cg-RX-API-DMAC7.html)
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2014511891A5 (cg-RX-API-DMAC7.html)
JP2014511892A5 (cg-RX-API-DMAC7.html)
JP2016503799A5 (cg-RX-API-DMAC7.html)
JP2010524932A5 (cg-RX-API-DMAC7.html)
JP2015520140A5 (cg-RX-API-DMAC7.html)
JP2014507455A5 (cg-RX-API-DMAC7.html)
JP2014508811A5 (cg-RX-API-DMAC7.html)
JP2019516739A5 (cg-RX-API-DMAC7.html)
JP2014508804A5 (cg-RX-API-DMAC7.html)
JP2015516427A5 (cg-RX-API-DMAC7.html)
JP2016516043A5 (cg-RX-API-DMAC7.html)
JP2016515561A5 (cg-RX-API-DMAC7.html)
JP2015537020A5 (cg-RX-API-DMAC7.html)
JP2015504081A5 (cg-RX-API-DMAC7.html)
JP2014523851A5 (cg-RX-API-DMAC7.html)
JP2013508279A5 (cg-RX-API-DMAC7.html)
JP2016503052A5 (cg-RX-API-DMAC7.html)
JP2016505614A5 (cg-RX-API-DMAC7.html)
JP2017517565A5 (cg-RX-API-DMAC7.html)
JP2011527299A5 (cg-RX-API-DMAC7.html)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1